<DOC>
	<DOCNO>NCT00199758</DOCNO>
	<brief_summary>The optimal strategy advance non small cell lung cancer stable disease well know . There publish study assess early change chemotherapeutic drug patients.Accordingly , conduct trial objective improve rate objective response switch another doublet 2 cycle CDDP-gemcitabine association patient stable disease ( SD ) .</brief_summary>
	<brief_title>Study Early Change Chemotherapeutic Doublet Versus Four Cycles Chemotherapy Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description>Patients stage IV NSCLC measurable disease include randomized phase II trial compare patient stable disease 2 cycle platin ( P ) -gemcitabine doublet ( P d1 : 75 mg/m2 , gemcitabine 1 250 mg/m2 d1 , d8 every three week ) two subsequent cycle doublet ( arm A ) switch another doublet ( arm B ) : paclitaxel 100 mg/m2 d1 , d8 , d15 , gemcitabine 1 250 mg/m2 d1 , d8 , every four weeks.Platin , gemcitabine paclitaxel administer accord nadir pre-cycle haematologic evaluation ( dose decrease need ) . Response criterion assess RECIST classification investigator panel .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically proved stage IV pleural stage III NSCLC ( neoplastic pleurisy confirm ) . Metastatic relapse allow irradiated area . Age 18 70 year Chemonaïve patient At least one measurable target lesion accord recist criterion non previously irradiate area . Performance status &lt; 2 Normal hepatic renal function , absolute neutrophil count &gt; 1,5 giga/l , platelet &gt; 100 giga/l . Written informed consent . Life expectancy &gt; 12 week . SCLC , bronchialalveolar neuroendocrine carcinoma . Previous chemotherapeutic treatment . Symptomatic brain metastasis . Superior vena cava syndrome . Other concomitant disease : heart failure , angina pectoris , arrhythmia , recent myocardial infarction . Peripheral neuropathy grade ≥2 . Past concomitance another cancer except basocellular carcinoma skin situ cervical carcinoma . Hypersensitivity paclitaxel polysorbate 80 . Pregnancy breast feed . Any concomitant radiotherapy , except palliative bone irradiation . Followup patient impossible . Prisoners .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Non small cell lung carcinoma</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>